A Phase II Study of CTLA Blockade by Ipilimumab Plus Androgen Suppression Therapy in Patients With an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs Ipilimumab (Primary) ; Antiandrogens
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 15 May 2018 Planned End Date changed from 18 Nov 2018 to 28 Sep 2018.
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2017 Planned End Date changed from 1 Apr 2018 to 18 Nov 2018.